ESTRO 2025 - Abstract Book

S2031

Clinical - Urology

ESTRO 2025

Conclusion: DOTA-2 showed that two-fraction DIL-boost delivered by MRgART without ADT are well-tolerated in terms of acute toxicity. Further follow-up is required.

Keywords: SBRT, DIL, MR Linac

References: 1. Ong, W. L.(2023). Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intraprostatic lesion-Results from the 2SMART phase 2 trial. Radiotherapy and oncology 2. Westley, R. L.(2024). Interim Toxicity Analysis From the Randomized HERMES Trial of 2- and 5-Fraction Magnetic Resonance Imaging-Guided Adaptive Prostate Radiation Therapy. 3. Ong, W. L.(2023). To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate Cancer. 4. Dankulchai, P.(2022). Feasibility and safety of definite volumetric modulated arc therapy with simultaneous integrated boost to the dominant intraprostatic lesion in patients with unfavorable intermediate to high-risk prostate cancer.